Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M87,130Revenue $M25,711Net Margin (%)7.8Z-Score2.5
Enterprise Value $M91,450EPS $2.0Operating Margin %11.8F-Score4
P/E(ttm))43.7Cash Flow Per Share $0Pre-tax Margin (%)9.2Higher ROA y-yN
Price/Book4.110-y EBITDA Growth Rate %10.5Quick Ratio0.9Cash flow > EarningsY
Price/Sales3.45-y EBITDA Growth Rate %-9.0Current Ratio1.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-31.7ROA % (ttm)3.5Higher Current Ratio y-yN
Dividend Yield %4.1Insider Buy (3m)0ROE % (ttm)8.8Less Shares Outstanding y-yN
Payout Ratio %174Shares Outstanding M1,263ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with AZN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AZNGeorge Soros 2014-06-30 Buy 0.08%$62.45 - $81.09
($72.26)
$ 69-4%New holding, 150000 sh.150,000
AZNMario Gabelli 2014-06-30 Buy 0.02%$62.45 - $81.09
($72.26)
$ 69-4%New holding, 40400 sh.40,400
AZNCharles Brandes 2014-06-30 Reduce-0.78%$62.45 - $81.09
($72.26)
$ 69-4%Reduce -71.06%386,058
AZNJoel Greenblatt 2014-06-30 Sold Out -0.09%$62.45 - $81.09
($72.26)
$ 69-4%Sold Out0
AZNNWQ Managers 2014-06-30 Reduce-0.01%$62.45 - $81.09
($72.26)
$ 69-4%Reduce -24.55%64,475
AZNJohn Hussman 2014-03-31 Add0.96%$58.51 - $68.15
($64.29)
$ 697%Add 714.29%228,000
AZNDavid Dreman 2014-03-31 Add0.14%$58.51 - $68.38
($64.41)
$ 697%Add 26.61%135,439
AZNJoel Greenblatt 2014-03-31 Buy 0.09%$58.51 - $68.38
($64.41)
$ 697%New holding, 95518 sh.95,518
AZNHOTCHKIS & WILEY 2014-03-31 Sold Out -0.93%$58.51 - $68.38
($64.41)
$ 697%Sold Out0
AZNCharles Brandes 2014-03-31 Reduce-0.84%$58.51 - $68.15
($64.29)
$ 697%Reduce -46.73%1,333,894
AZNDavid Dreman 2013-12-31 Reduce-0.34%$49.72 - $59.5
($54.28)
$ 6927%Reduce -40.32%106,975
AZNHOTCHKIS & WILEY 2013-12-31 Reduce-0.3%$49.72 - $59.5
($54.28)
$ 6927%Reduce -24.9%3,689,214
AZNJohn Hussman 2013-12-31 Reduce-0.11%$49.72 - $59.5
($54.28)
$ 6927%Reduce -58.82%28,000
AZNCharles Brandes 2013-09-30 Add0.12%$47.88 - $52.08
($50.24)
$ 6937%Add 7.92%2,381,040
AZNJohn Hussman 2013-09-30 Reduce-0.66%$47.88 - $52.08
($50.24)
$ 6937%Reduce -81.87%68,000
AZNHOTCHKIS & WILEY 2013-06-30 Add0.68%$47.22 - $53.01
($50.92)
$ 6936%Add 131.18%4,944,742
AZNJohn Hussman 2013-06-30 Reduce-1.02%$47.22 - $53.01
($50.92)
$ 6936%Reduce -59.76%375,000
AZNJoel Greenblatt 2013-06-30 Sold Out -0.24%$47.22 - $53.01
($50.92)
$ 6936%Sold Out0
AZNNWQ Managers 2013-03-31 Buy 0.03%$44.67 - $50.06
($47.4)
$ 6946%New holding, 78400 sh.78,400
AZNJohn Hussman 2013-03-31 Reduce-0.74%$44.67 - $50.06
($47.4)
$ 6946%Reduce -38.8%932,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AZN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AZN Mario Gabelli 2014-06-3040,40000.02New Buy
AZN George Soros 2014-06-30150,0000.010.08New Buy
AZN - CALLDaniel Loeb 2014-06-301,000,0000.080.91
AZN John Hussman 2014-06-30223,5000.021.3-1.97%
AZN David Dreman 2014-06-30117,8320.010.66-13%
AZN NWQ Managers 2014-06-3064,4750.010.05-24.55%
AZN Charles Brandes 2014-06-30386,0580.030.35-71.06%
AZN Joel Greenblatt 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


AZN: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about AZN :

    Quarterly/Annual Reports about AZN:

      News about AZN:

      Articles On GuruFocus.com
      Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
      I Believe AstraZeneca Is Fairly Valued Jul 16 2014 
      A Look at AstraZeneca’s New Drug on Diabetes May 22 2014 
      Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
      Can Pfizer Make Up Its Loss? May 09 2014 
      Abbott Capturing Incremental Market Share Mar 18 2014 
      Abbvie's Humira Continues to be a Powerful Catalyst for Growth Mar 18 2014 
      10 British Stocks to Consider Feb 20 2014 
      Bristol-Myers: Don’t Let This One Get Away Jan 15 2014 
      AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is Jan 15 2014 


      More From Other Websites
      Markets open for trading: AbbVie/Shire deal scrapped Oct 21 2014
      Will GlaxoSmithKline (GSK) Earnings Suffer on China Probe? Oct 20 2014
      The shares tipped to fall if Labour wins next year’s general election Oct 20 2014
      BUZZ-European healthcare: safety check Oct 20 2014
      Pfizer/AZ chase may be off as pharma deals falter Oct 20 2014
      Ironwood/Actavis Move Linzess into Phase II Study for OIC Oct 17 2014
      Why AQR Capital exits its position in Tableau Software Inc. Oct 17 2014
      Roche, Merck extend immunotherapy fight to breast cancer Oct 17 2014
      Why AQR Capital opens a new position in Equinix Oct 16 2014
      Tax inversion clampdown leaves M&A engineers seeking new oil for the deal machine Oct 16 2014
      Questor special: FTSE 100 defensive shares for a market panic Oct 16 2014
      Why AQR Capital starts a new position in Navient Oct 16 2014
      Why AQR Capital opens new a position in AstraZeneca Oct 16 2014
      How Much Lower Can Shire PLC Go? Oct 16 2014
      Why Smith & Nephew plc’s Latest Failure Should Worry AstraZeneca plc And GlaxoSmithKline plc Oct 16 2014
      AstraZeneca strengthens partnership with the University of Cambridge Oct 16 2014
      Shire - AbbVie: Turning the screw on tax inversions Oct 15 2014
      Overview: AQR Capital Management’s 2Q14 positions Oct 15 2014
      FTSE 100 teetering on edge of correction; Shire sinks in London Oct 15 2014
      Shire Falls, AbbVie Questioned On Buyout Backtrack Oct 15 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK